{"entity":{"id":"lyvgen-biopharma","kind":"company","name":"Lyvgen Biopharma","aka":["Lyvgen Biopharma Holdings","礼进生物"],"tldr":"Lyvgen Biopharma is a Shanghai antibody company that builds agonists of immune-activating receptors such as CD137 and CD40; its CD137 antibody LVGN6051 is being tested with PD-1 blockade.","summary":"Lyvgen Biopharma develops next-generation immuno-oncology antibodies with engineered Fc regions that tune their crosslinking and activity. LVGN6051 is a CD137 (4-1BB) agonist designed to activate T cells within tumours while limiting the liver toxicity seen with earlier agents; it is in phase 1 trials alone and with pembrolizumab or anlotinib. LVGN7409 is a CD40 agonist and LVGN3616 is a PD-1 antibody.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lyvgen.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lvgn6051"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.lyvgen.com/","investors":[],"funding":[]},"route":"/companies/lyvgen-biopharma/","neighbours":{"drug":[{"id":"lvgn6051","kind":"drug","name":"LVGN6051","route":"/drugs/lvgn6051/"}]}}